Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab versus infliximab in pediatric moderate-to-severe active ulcerative colitis
MOH_2019-02-14_004871Phase 3Completed
- Sponsor
- Janssen-Cilag
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of golimumab in autoimmune colitis (2 arms), sponsored by Janssen-Cilag. Started Aug 2018; status: completed.
02
Drugs
golimumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2019-02-14_004871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-14_004871.